WuXi AppTec IPO Valuation: Bull/Bear Case DCF Scenarios
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
534 Views
Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO
Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the...
1.1k Views
WuXi Apptec (药明康德) IPO:Upside at Middle and Low End
Wuxi Apptec launched book building today with a price range of HKD 64.10 to HKD 71.50, planning to raise USD 954 million to USD 1,064 million. In...
751 Views
WuXi AppTech IPO Update: Figuring Out the Right AH Premium
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
722 Views
Wuxi Apptec 药明康德 IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
853 Views